Personalized treatment options for endometrial cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of different adjuvant therapies for women with stage I-II high-intermediate or high-risk endometrial carcinoma based on molecular classification. The study compares chemotherapy versus chemoradiotherapy for the p53 abnormal subtype and nonendometrioid carcinomas, as well as vaginal brachytherapy versus whole pelvic radiotherapy for the MMR-D and NSMP molecular subgroups. It is designed as a multicenter prospective trial, with a focus on improving treatment outcomes through personalized medicine. The primary outcome is the 5-year cumulative incidence of disease recurrence, while secondary outcomes include various recurrence rates and patient-reported symptoms.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 100 years
* WHO performance status 0 to 2
* Stage I-II molecular integrated high-intermediate or high-risk endometrial carcinoma

Exclusion Criteria:

* Age \<18 years or \>100 years
* WHO performance status \>2
* Uterine sarcoma
* A history of malignancy within 5 years
* Previous pelvic radiotherapy
* An interval of \>30 days between surgery and start of chemotherapy or \>8 weeks between surgery and start of radiotherapy (longer intervals may be permitted with investigator´s approval)

Where it's running

• Helsinki University Hospital
  Helsinki, Finland Recruiting

Study contacts

• Principal investigator: Mikko Loukovaara — Helsinki University Central Hospital
• Study coordinator: Mikko Loukovaara
• Email: mikko.loukovaara@hus.fi
• Phone: +358504272526

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer: Safety, Efficacy, and Quality of Life

  This study tests whether a shorter course of pelvic radiotherapy is safe and effective for women with non-metastatic endometrial cancer, and how it affects their quality of life.

  Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07871838

• One year vs two years of maintenance immunotherapy for endometrial cancer

  This trial tests whether keeping pembrolizumab or dostarlimab for one year works as well as two years for people with advanced, recurrent, or metastatic endometrial cancer who completed initial chemo and anti-PD1 therapy.

  Recruiting at 6 sites Phase 3 UNC Lineberger Comprehensive Cancer Center · Cary, North Carolina and 5 other locations · NCT07867002

• DBC-664 in adults with solid tumors

  A first-in-human study will test DBC-664 to see if it is safe and tolerable in adults with various advanced solid tumors and may hint at anti-tumor activity.

  Recruiting at 7 sites Phase 1 TCG Labs Soleil · Denver, Colorado and 6 other locations · NCT07705035

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Fertility-preserving hysteroscopic treatment outcomes for endometrial cancer and atypical hyperplasia

  This project tests whether removing lesions by hysteroscopy combined with hormonal therapy helps women with endometrial cancer or atypical hyperplasia preserve fertility and achieve good pregnancy and cancer-control outcomes.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07077876

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.